Clinical Trial Detail

NCT ID NCT03588039
Title Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Athenex, Inc.
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Oraxol + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.